🛡️ Hazard Overview
- GHS Class: None
- Signal Word: Not applicable
- Hazard Statements: None
🧤 PPE Guidelines
- Gloves: Chemical‑resistant gloves suggested
- Eye Protection: Safety goggles suggested
- Respirator: Dust respirator if dust occurs
❄️ Storage
- Storage Temp: -20°C (-4°F) Keep dry
🚑 Emergency First Aid
- For inhalation, skin, eye or ingestion exposure, please refer to full SDS Section 4.
Product identifier
- Product Name: Iodixanol
- Catalog Number: S5218
- CAS Number: 92339-11-2
- IUPAC Name: 1,3-Benzenedicarboxamide, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
Relevant identified uses and uses advised against
- Identified uses: For research and development use only; laboratory chemicals; manufacture of substances.
- Uses advised against: Not for pharmaceutical, household, or other unapproved uses.
Details of the supplier
- Company: Selleck Chemicals
- TollFree: +1 877 796-6397
- Tel: +1 832 582-8158
- Fax: +1 832 582-8590
Emergency telephone number
- Emergency phone #: +1 832 582-8158
2.1 GHS classification in accordance with 29 CFR 1910 (OSHA HCS):
Not classified as a hazardous substance according to GHS.
2.2 GHS Label elements, including precautionary statements
Hazard Pictogram(s):
None.
Signal Word:
Not applicable
Hazard statement(s):
None.
Precautionary statement(s):
None.
2.3 Other hazards
None.
3.1 Substances
Product name: Iodixanol
CAS Number: 92339-11-2
PubChem CID: 3724
Molecular formula: C35H44I6N6O15
Molecular weight: 1550.2 g/mol
IUPAC name: 5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
3.2 Mixtures
Not applicable (pure substance).
4.1 Description of first aid measures
Inhalation: Move to fresh air. Keep at rest in a position comfortable for breathing. Seek medical attention if symptoms persist.
Skin contact: Wash with plenty of soap and water. Remove contaminated clothing. Seek medical attention if irritation develops.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention.
Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.
4.2 Most important symptoms and effects, both acute and delayed
See Section 11 (Toxicological Information).
4.3 Indication of any immediate medical attention and special treatment needed
Treat symptomatically. Contact a poison control center or physician for severe exposure.
5.1 Extinguishing media
Suitable: Water spray, dry chemical, carbon dioxide (CO2), alcohol-resistant foam.
Unsuitable: None known.
5.2 Specific hazards arising from the substance or mixture
As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.
5.3 Advice for firefighters
Wear self-contained breathing apparatus (SCBA) and full protective clothing.
Fight fire from upwind. Cool containers with water spray until fire is extinguished.
6.1 Personal precautions, protective equipment and emergency procedures
Wear appropriate personal protective equipment (see Section 8).
Avoid breathing dust/vapor. Ensure adequate ventilation.
Evacuate personnel to safe areas. Keep people away from and upwind of spill.
6.2 Environmental precautions
Prevent product from entering drains, waterways, or soil.
Contain spill with inert absorbent material.
6.3 Methods and materials for containment and cleaning up
Wear approved respiratory protection, chemically compatible gloves, and protective clothing. Wipe up spillage or collect spillage using a high-efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
SRP: Wastewater from contaminant suppression, cleaning of protective clothing/equipment, or contaminated sites should be contained and evaluated for subject chemical or decomposition product concentrations. Concentrations shall be lower than applicable environmental discharge or disposal criteria. Alternatively, pretreatment and/or discharge to a permitted wastewater treatment facility is acceptable only after review by the governing authority and assurance that "pass through" violations will not occur. Due consideration shall be given to remediation worker exposure (inhalation, dermal and ingestion) as well as fate during treatment, transfer and disposal. If it is not practicable to manage the chemical in this fashion, it must be evaluated in accordance with EPA 40 CFR Part 261, specifically Subpart B, in order to determine the appropriate local, state and federal requirements for disposal.
As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly.
As with all dry powders, it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.
SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.
SRP: Contaminated protective clothing should be segregated in such a manner so that there is no direct personal contact by personnel who handle, dispose, or clean the clothing. The completeness of the cleaning procedures should be considered before the decontaminated protective clothing is returned for reuse by the workers. Contaminated clothing should not be taken home at the end of shift, but should remain at employee's place of work for cleaning.
7.1 Precautions for safe handling
Store in tight container ... . This material should be handled and stored per label instructions to ensure product integrity.
7.2 Conditions for safe storage, including any incompatibilities
Store in tight container ... . This material should be handled and stored per label instructions to ensure product integrity.
Store away from incompatible materials (see Section 10).
[Note: Specific storage temperature not available in public databases. Refer to supplier Certificate of Analysis (COA) for exact storage conditions.]
8.1 Exposure controls
8.1.1 Occupational exposure limits (OEL)
OSHA PEL: Not established.
ACGIH TLV: Not established.
NIOSH REL: Not established.
No occupational exposure limit values are established for this substance.
Use the lowest feasible exposure level (ALARA principle).
8.1.2 Appropriate engineering controls
Use in a well-ventilated area. Chemical fume hood recommended for powder handling.
8.2 Individual protection measures
8.2.1 Eye/face protection
Wear safety glasses with side shields.
8.2.2 Skin protection
Wear protective gloves. Recommended material: Nitrile rubber.
Wear suitable protective clothing (lab coat).
8.2.3 Respiratory protection
Respiratory protection usually not required under normal use with adequate ventilation.
Use N95 respirator for large-scale powder handling.
8.2.4 Thermal hazards
Not applicable.
9.1 Information on basic physical and chemical properties
a) Appearance: Solid
b) Odor: No data available
c) Odor threshold: No data available
d) pH: 7.2-7.6 (c = 320 mg I/L)
e) Melting point/freezing point: 240-250 °C
f) Initial boiling point and boiling range: No data available
g) Flash point: No data available
h) Evaporation rate: No data available
i) Flammability (solid, gas): No data available
j) Upper/lower flammability or explosive limits: No data available
k) Vapor pressure: No data available
l) Vapor density: No data available
m) Relative density: 1.266
n) Water solubility: Soluble in water
o) Partition coefficient: n-octanol/water: Log P (n-octanol/water): -3.4
p) Auto-ignition temperature: No data available
q) Decomposition temperature: No data available
r) Viscosity: 11.1 mPa at 37 °C
s) Explosive properties: No data available
t) Oxidizing properties: No data available
9.2 Other information
Topological Polar Surface Area (TPSA): 339 Ų
Complexity: 1330
10.1 Reactivity
No specific reactivity hazards identified under normal handling conditions.
10.2 Chemical stability
Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions
No hazardous reactions under normal conditions.
10.4 Conditions to avoid
Avoid heat, sparks, open flames, direct sunlight, and moisture.
Avoid strong oxidizing agents, strong acids, and strong bases.
10.5 Incompatible materials
/Investigators sought/ to test the compatibility of trisodium citrate, a catheter lock solution, with iodinated contrast medium. ...Ioxaglate... was tested. In all tests, 2 mL of contrast medium were mixed with 2 mL of trisodium citrate solution. ...Ioxaglate provoked a highly viscous gluelike precipitation when mixed with trisodium citrate. /It was concluded that/one must be aware of the potential for precipitation when contrast medium is mixed with trisodium citrate solution. Before trisodium citrate solution is injected, the catheter should be thoroughly flushed with saline if a contrast medium has previously been injected through it.
10.6 Hazardous decomposition products
Thermal decomposition may produce: Carbon monoxide (CO), Carbon dioxide (CO₂), Nitrogen oxides (NOx).
See also Section 5 (Fire-fighting measures) for combustion products.
11.1 Information on toxicological effects
Acute toxicity:
No acute toxicity data available.
Skin corrosion/irritation:
No data available.
Serious eye damage/eye irritation:
No data available.
Respiratory or skin sensitization:
No data available.
Germ cell mutagenicity:
No data available.
Carcinogenicity:
No data available.
Reproductive toxicity:
No data available.
Specific target organ toxicity (single exposure):
No data available.
Specific target organ toxicity (repeated exposure):
No data available.
Aspiration hazard:
No data available.
11.2 Additional information
No additional toxicological information available.
12.1 Toxicity
DRINKING WATER: It has been suggested that in all countries with an advanced medical care system, x-ray contrast media can be expected to be present in sewage effluent which, therefore, leads to potential contamination of receiving waters(1).
Occupational exposure to iodixanol may occur through inhalation and dermal contact with this compound at workplaces where iodixanol is produced or used. Exposure to iodixanol among the general population may include those administered this contrast agent. (SRC)
12.2 Persistence and degradability
No data available.
12.3 Bioaccumulative potential
Log P (n-octanol/water): -3.4
Low potential for bioaccumulation (Log P < 3).
12.4 Mobility in soil
No data available.
12.5 Results of PBT and vPvB assessment
PBT/vPvB assessment not available.
12.6 Other adverse effects
No other adverse ecological effects identified.
13.1 Waste treatment methods
Waste Treatment Methods: Waste material must be disposed of in accordance with national and local regulations. Leave chemicals in original containers and do not mix with other waste. Handle uncleaned containers in the same manner as the product itself.
14.1 UN number
Not regulated as dangerous goods (research quantities typically exempt).
14.2 UN proper shipping name
Not subject to transport regulations (small quantities for research use).
14.3 Transport hazard class(es)
Not classified as dangerous goods for transport (research quantities).
14.4 Packing group
Not applicable (not regulated as dangerous goods in typical research quantities).
14.5 Environmental hazards
Marine pollutant: No (not classified as environmentally hazardous per GHS).
14.6 Special precautions for user
Transport in original packaging. Ensure containers are tightly sealed.
For bulk or commercial quantities, consult applicable transport regulations (DOT, IATA, IMDG).
14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable.
15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
US EPA / TSCA: Not available in public databases.
EU ECHA / REACH: Registered (REACH Active)
SARA 302 Components:
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components:
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards:
No SARA Hazards.
Massachusetts Right To Know Components:
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components:
No components are subject to the Pennsylvania Right to Know Act.
New Jersey Right To Know Components:
No components are subject to the New Jersey Right to Know Act.
California Prop. 65 Components:
This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.
Other regulatory listings:
- FDA Requirements: The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including iodixanol, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
15.2 Chemical safety assessment
A chemical safety assessment has not been carried out for this substance.
For research-use-only compounds, no CSA is required under REACH Annex I.
Revision Date: 2026/09/09
Further Information: The information provided is believed to be correct but is not exhaustive and should be used only as a guideline based on current knowledge. It does not represent a guarantee of the properties of the product. Selleck Chemicals Corporation and its Affiliates shall not be held liable for any damage resulting from handling or contact with the product.